Safety reviews are also on the FDA's agenda, with Dr Prasad stating the agency will look to use big data for enhanced safety signal analysis. Cell and gene therapy safety sadly hit the news for another reason this week, when Sarepta's Elevidys (delandistrogene moxeparvovec) was linked to a second patient death.